Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New obesity drug passes early safety check

NCT ID NCT06557356

First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 26 times

Summary

This early-stage study tested a new drug called LY3532226 in 132 people with obesity to see if it is safe and how the body processes it. Participants received weekly or monthly doses, and researchers monitored side effects and drug levels in the blood. The goal was to gather safety information, not to measure weight loss.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida, 32117, United States

  • Fortrea Clinical Research Unit

    Dallas, Texas, 75247, United States

  • Fortrea Clinical Research Unit

    Madison, Wisconsin, 53704, United States

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623, Singapore

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.